Case 27. What’s New from AIDS 2026 in Brazil with Dr. Joel Gallant
Download MP3Dr. Joel Gallant joins host Chris Hoffmann of Johns Hopkins to review new data and developments from the 26th International AIDS Conference (AIDS 2026), which was held in Brazil in July. They focus on abstracts that have implications for HIV care.
Reference:
Reference:
- Perez Navarro A, Nutt CT, Siedner MJ, McCluskey SM, Hill A. Virologic Failure and Emergent Integrase Strand Transfer Inhibitor Drug Resistance With Long-Acting Cabotegravir for HIV Treatment: A Meta-analysis. Clin Infect Dis. 2025 Sep 16;81(2):274-285. PMID: 39724249.
Abstracts cited from AIDS 2026, the 26th International AIDS Conference:
Abstracts discussed by Chris and Joel are listed below in alphabetical order by first author’s last name. All abstracts are available online: JIAS. Volume 29, Issue S4 Supplement: Abstracts From AIDS 2026, the 26th International AIDS Conference, 26 – 31 July 2026 Rio de Janeiro, Brazil & virtual July 2026. JIAS makes abstracts available as an Epub and a PDF.
Abstracts discussed by Chris and Joel are listed below in alphabetical order by first author’s last name. All abstracts are available online: JIAS. Volume 29, Issue S4 Supplement: Abstracts From AIDS 2026, the 26th International AIDS Conference, 26 – 31 July 2026 Rio de Janeiro, Brazil & virtual July 2026. JIAS makes abstracts available as an Epub and a PDF.
- Colson AE, Kumar PN, Ruane PJ, et al. OAX1106LB: Once-Weekly Oral Islatravir/Lenacapavir (ISL/LEN) Versus Daily Standard-of-Care Therapy in Virologically Suppressed Adults With HIV-1: Week 48 Results of the ISLEND-2 Phase 3 Trial
- Dangarembizi MB, Chappell E, Kekitiinwa AR, et al. OAX1105LB: Every-8-Weeks Injectable Cabotegravir and Rilpivirine is Superior to Daily Oral Tenofovir Disoproxil Fumarate/Lamivudine/Dolutegravir in Adolescents Living With HIV in Sub-Saharan Africa: LATA 96-Week Results
- Di Gregorio S, Brun LR, Mourelo S, et al. OAB3405: The Body Composition Signature of Switching to BIC/FTC/TAF or DTG/3TC Over 96 Weeks
- Dsouza G, Olshan S, Lahiri C, et al. TUPEB082: Risk of HPV-related cancers remain higher among people living with HIV in the ART era: evidence from a large U.S. cohort (MWCCS)
- Ghosn J, Pulido F, Lopardo GD, et al. OAB0106LB In VOGUE: DTG/3TC 2-Drug Regimen is Non-Inferior to BIC/FTC/TAF 3-Drug Regimen in a Randomized Trial in Adults With HIV Naive to Treatment
- Jacobs J, Hoagland B, Coutinho C, et al. OAC2803: Challenges in Early HIV Detection During CAB-LA PrEP: Characterization of Inconclusive Serological Results in ImPrEP CAB Brasil
- Kiwanuka N, Malahleha M, Nair G, et al. OAC2802: Zero HIV Acquisitions With Twice-Yearly Subcutaneous Lenacapavir for PrEP During 52 Weeks of Open-Label Extension in PURPOSE 1
- Losso M, Santos B, Lama JR, et al. OAC2806LB: High Efficacy of Twice-Yearly Subcutaneous Lenacapavir for PrEP Through 52 Weeks of Open-Label Extension in PURPOSE 2
- Luetkemeyer AF, Bloch M, Scribner A, et al. OAB1405LB: Randomized, Active-Controlled, Phase 2b Study Evaluating Efficacy and Safety of Switch to Islatravir (ISL) 2 mg With Ulonivirine (ULO) 200 mg Once Weekly in Virologically Suppressed Adults Living With HIV-1.
- McMahon J, Eron J, Gaur A, et al. OAB1403: Efficacy and Safety of Twice-Yearly Lenacapavir, Teropavimab and Zinlirvimab as an HIV-1 Treatment for up to 104 Weeks
- Niehaus ED, McKellar MS, Kenny A, Okeke NL. OAC4205: Real-World Effectiveness of Doxycycline Post-Exposure Prophylaxis for STI Prevention in a Southern U.S. HIV/PrEP Clinic
- Rockstroh JK, Ramgopal MN, Fabregas AC, et al. OAB1406LB: Once-Weekly Oral Islatravir/Lenacapavir (ISL/LEN) Versus Daily Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed Adults With HIV-1: Week 48 Results of the ISLEND-1 Phase 3 Trial
- Saidi F, Squibb MA, Masano A, et al. OAC1306LB: Interim Analysis of Adverse Pregnancy Outcomes With Injectable CAB-LA Versus Oral PrEP: Findings From the PrIMO Safety Cohort
- Siegler A, Koh E, Corbin-Gutierrez E, et al. OAC1906LB: The First 6 Months of National Injectable Lenacapavir PrEP Prescribing and Equity, United States, June−December 2025
- Wang R, Chen W, Kumar A, et al. OAB2306LB: The Impact of Archived HIV-1 Drug Resistance on Maintenance of Virologic Suppression Through Week 48 in Children Aged 2 to <15 Years Receiving DTG/3TC: PENTA-21 Intensive Pharmacokinetic Sub-Study
- Woods J, Lebina L, Moller K, et al. OAB3406LB Opti-DOR: 48Week Data on DOR/3TC/TDF as an Alternative First-Line Antiretroviral Therapy (ART) Regimen to Integrase Inhibitors for People With HIV and BMI>25 kg/m2 in a Randomized Phase 3B Non-Inferiority Study
Related NYSDOH AI Guidelines:
- Doxycycline Post-Exposure Prophylaxis to Prevent Bacterial Sexually Transmitted Infections
- Immunizations for Adults With HIV
- PEP to Prevent HIV Infection
- PrEP to Prevent HIV and Promote Sexual Health
- Prevention and Management of Hepatitis B Virus Infection in Adults With HIV
- Prevention and Management of Human Papillomavirus Infection in Adults With HIV
- Primary Care for Adults With HIV
- Rapid ART Initiation
- Selecting an Initial ART Regimen
- Screening for Anal Dysplasia and Cancer in Adults With HIV
- Screening for Cervical Dysplasia and Cancer in Adults With HIV
- Use of Injectable CAB/RPV LA as Replacement ART
